Journal of Clinical Oncology
Articles in this Issue
Associations of DNA damage repair (DDR) pathway class and allelic configuration with survival in metastatic renal cell carcinoma.
455 Background: Alterations in DNA damage repair (DDR) pathways occur in a subset of metastatic renal cell carcinoma (mRCC...
Outcomes of delayed cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitor therapy.
462 Background: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has evolved in the im...
Does time to recurrence after radical cystectomy for bladder cancer impact subsequent survival?
874 Background: It has been long theorized that patients with earlier recurrence after radical cystectomy (RC) for bladder...
Contemporary analysis of the prognostic significance of intraductal carcinoma of the prostate (IDC-P).
126 Background: IDC-P has become increasingly recognized for its poor prognosis among histologic subtypes. While prior stu...
Trends in high grade prostate cancer at diagnosis in the United States from 2004-2022.
341 Background: Prostate cancer represents a heterogeneous disease with varying clinical significance, from indolent cases...
Clinical efficacy of belzutifan in pre-treated renal cell carcinoma: A real world retrospective cohort benchmarked to LITESPARK-005.
464 Background: Based on LITESPARK-005 trail, Belzutifan was FDA-approved to treat advanced RCC following ICI and a VEGF-T...
Effect of epidural analgesia vs. combined intravenous patient-controlled analgesia and transversus abdominis plane block on postoperative outcomes after radical cystectomy.
875 Background: Intravenous patient-controlled analgesia (IV-PCA) and epidural analgesia are commonly used methods for pos...
Severe acute kidney injury after abiraterone vs enzalutamide in advanced prostate cancer: A SEER–Medicare study.
120 Background: Acute kidney injury (AKI) is a frequent complication among older adults with cancer, linked to short-term...
Salvage radiotherapy after radical prostatectomy in a Japanese cohort: Analysis from the MICAN study.
342 Background: The clinical benefit of salvage radiotherapy (SRT) for biochemical recurrence (BCR) after radical prostate...
TANKeR-70: TGF-β-receptor type 2 knockout allogeneic NK cells for renal cell carcinoma expressing CD70.
TPS571 Background: Clear cell renal cell carcinoma (ccRCC) frequently expresses CD70. Chimeric antigen receptor (CAR) natu...
Patient-derived primary prostate cancer epithelial cultures for studying prostate cancer cell evolution under hypoxia.
397 Background: Genetic instability is a hallmark of cancer and a driving force of tumourigenesis. An emerging concept is...
Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.
192 Background: BCR pts have a rising PSA after definitive surgery or radiation, but negative CT/Tc-99m bone scans. While...
Real world outcomes comparing the use of GLP-1 agonists in patients with bladder cancer and comorbid obesity: A propensity score matched analysis from the Global Federated Health Research Network.
712 Background: Bladder cancer is one of the most common malignancies of the urinary tract. Glucagon-like peptide-1 (GLP-1...
Ivonescimab in metastatic clear cell renal cell carcinoma (mccRCC) after immune checkpoint inhibitor therapy: The phase II IVORY trial.
TPS573 Background: ICI-based combinations, as dual ICIs or ICI plus a vascular endothelial growth factor tyrosine kinase i...
Impact of intraoperative frozen section analysis (NeuroSAFE) on oncologic and functional outcomes after radical prostatectomy: A systematic review and meta-analysis.
373 Background: The NeuroSAFE technique, which provides intraoperative frozen section analysis of the neurovascular bundle...
HER2 expression and genomic alterations in plasmacytoid urothelial carcinoma: Results from a large real-world institutional cohort.
803 Background: Plasmacytoid urothelial carcinoma (PUC) is a rare and aggressive histologic subtype of urothelial carcinom...
Efficacy of rezvilutamide in preventing the flare phenomenon induced by GnRH agonists in newly diagnosed metastatic hormone-sensitive prostate cancer: An exploratory multicenter randomized controlled trial.
191 Background: Current guidelines recommend first-generation antiandrogens ≥7 days before or concomitant with gonadotropi...
Association of coexisting amyloidosis with survival outcomes in bladder cancer: A real-world cohort study.
650 Background: Bladder cancer (BC) is one of the most prevalent urologic malignancies. Amyloidosis, characterized by extr...
Neoadjuvant (Neoadj) gemcitabine intravesical system (Gem-iDRS) plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for/refusing neoadj cisplatin-based chemotherapy (NAC): Updated perioperative outcomes from SunRISe-4.
748 Background: There is a high unmet need for effective neoadj treatments (tx) for MIBC that maintain overall health and...
Baseline biochemical and clinical predictors of castration resistance and survival in metastatic hormone-sensitive prostate cancer treated with first-line androgen receptor pathway inhibitors: A multicenter real-world study.
108 Background: Androgen receptor pathway inhibitors (ARPIs) plus androgen deprivation therapy (ADT), with or without doce...
Low-coverage whole-genome sequencing of urinary tumor DNA to characterize genomic correlates of lymphovascular invasion in bladder cancer.
804 Background: Lymphovascular invasion (LVI) is a key pathological feature linked to tumor dissemination and poor outcome...
CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
416 Background: Patients (pts) presenting with de novo metastatic renal cell carcinoma (mRCC) have a poor prognosis. The r...
Rethinking germline testing in localized prostate cancer: Prevalence of germline variants and association with Gleason score and NCCN risk grouping.
322 Background: Men with prostate cancer who harbor germ-line pathogenic variants have increased likelihood of a more aggr...
Impact of androgen receptor pathway inhibitor (ARPI) dose reduction on overall survival of metastatic castration-resistant prostate cancer: A multi-centre retrospective study.
115 Background: Androgen receptor pathway inhibitors (ARPIs) have been a cornerstone in the management of metastatic castr...
Quantifying the hidden burden of metastatic prostate cancer.
96 Background: Preventing metastatic disease is the key goal of prostate cancer screening and local treatment. However, mo...